Back to Annual Meeting

Back to Annual Meeting

APHA Scientific Session and Event Listing

Recorded presentation

Katrina Park, MPH¹, Jennifer Wright, DVM, MPH, DACVPM¹, Susan Fuller, MBS², Paul Hug, CLS, NCA³, Ajaib Singh, DVM, PhD⁴, Richard Steece, PhD, D(ABMM)⁵, Anthony Tran, MPH, MT(ASCP)⁶, Scott Zimmerman, DrPH, MPH⁷, David L. Trees, PhD⁸, and Hillard Weinstock, MD, MPH¹. (1) Division of STD Prevention, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop E-02, Atlanta, GA 30333, 404-639-1807, KPark2@cdc.gov, (2) MN Department of Health, Public Health Laboratory, 601 Robert Street North, PO Box 64899, St. Paul, MN 55164-0899, (3) Nevada State Public Health Laboratory System, Southern Nevada Public Health Laboratory (SNPHL), P O Box 3902, Las Vegas, NV 89127, (4) Milwaukee Health Department Laboratories, 841 N Broadway, Room 205, Milwaukee, WI 53202-3659, (5) National Infertility Prevention Project, 1811 Flag Mountain Drive, Pierre, SD 57501, (6) Association of Public Health Laboratories, 2025 M Street, NW, Suite 550, Washington, DC 20036, (7) Erie County Regional Public Health Laboratories, Clinical Center Building AA, 462 Grider Street, Buffalo, NY 14215, (8) Gonorrhea Molecular Epidemiology Lab, Centers for Disease Control and Prevention, 1600 Clifton Road, Mailstop C13, Atlanta, GA 30329-4018

Objectives: National surveillance for antimicrobial resistant Neisseria gonorrhoeae has been limited to men. Due to the increasing prevalence of fluoroquinolone-resistant Neisseria gonorrhoeae (QRNG) in men, we examined prevalence data for women from 2 sources.

Methods: The Gonococcal Surveillance Project (GSP), a joint project between the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL), collected data from women presenting to STD and family planning clinics for routine care in three U.S. cities. Participants were cultured for gonorrhea between March and December 2005. Additional data were collected by surveying 24 state and local health departments which had previously reported performing N. gonorrhoeae susceptibility testing.

Results: Of the 24 health department laboratories performing susceptibility testing, 15 provided data on women, demonstrating that 1.3% (14/1086) of isolates were resistant to quinolones. Preliminary GSP data demonstrated a QRNG prevalence of 1.1% (3/280).

Conclusions: We assessed QRNG prevalence among women by comparing data from two sources, demonstrating that the prevalence of QRNG among women is comparable to the prevalence previously reported among heterosexual men. These data demonstrate that QRNG prevalence is low enough among women and heterosexual men that fluoroquionolnes remain a viable treatment option for these populations in most of the country.

Learning Objectives:

• To examine prevalence of fluoroquinolone resistant neisseria gonorrhoeae (QRNG) among women in the United States.

Keywords: STD, Epidemiology

Presenting author's disclosure statement:

Any relevant financial relationships? No

Recorded presentation